<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886674</url>
  </required_header>
  <id_info>
    <org_study_id>Bovine Colostrum in NEC</org_study_id>
    <nct_id>NCT04886674</nct_id>
  </id_info>
  <brief_title>Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates</brief_title>
  <official_title>Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates: a Prospective Study at Neonatology Unit of Children's Hospital Assiut University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Aim: The aim of this study is to investigate the efficacy of bovine colostrum in&#xD;
      prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW)&#xD;
      infants.&#xD;
&#xD;
      Secondary Aim: To improve outcomes of neonatal sepsis and NEC in the pe-terrms and to&#xD;
      decrease their hospital stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Necrotizing enterocolitis (NEC) primarily occurs in premature and very low birth weight&#xD;
      (VLBW) babies, the incidence varying from 5 to 10% in various neonatal intensive care unit&#xD;
      (NICUs) .&#xD;
&#xD;
      Many researchers believe that an exaggerated inflammatory response mounted by immature&#xD;
      intestinal epithelial cells in response to abnormal intestinal colonization plays a vital&#xD;
      role in the pathogenesis of NEC and bacteria belonging to Enterobacteriaceae have often been&#xD;
      linked to NEC .&#xD;
&#xD;
      Colonization with commensal bacteria soon after birth is essential for the development of&#xD;
      normal intestinal function however, this process is often altered in premature babies in&#xD;
      NICUs, leading to colonization with pathogenic bacteria .&#xD;
&#xD;
      Commercially available bovine colostrum has high concentrations of anti-infective factors&#xD;
      such as immunoglobulins, lactoferrin, organism-specific antibodies, lactoperoxidase,&#xD;
      insulin-like growth factors and transforming growth factors.&#xD;
&#xD;
      These components have substantial homology to their human counterparts . Bovine colostrums&#xD;
      has been tried in the treatment of Escherichia coli and Shigella and Rotavirus diarrhea in&#xD;
      children, Helicobacter pylori infection in children and E. coli intestinal infection in term&#xD;
      and preterm neonates.&#xD;
&#xD;
      No major adverse effects were reported in any of the studies using bovine colostrum in&#xD;
      infants and preterm babies .&#xD;
&#xD;
      In an in vitro study, the authors showed that bovine colostrum significantly reduces the&#xD;
      adherence of various Enterobacteriaceae species known to be associated with NEC to human&#xD;
      intestinal epithelial cells .&#xD;
&#xD;
      A randomized controlled trial has shown that the use of bovine lactoferrin reduced the&#xD;
      incidence of neonatal sepsis .&#xD;
&#xD;
      Till date, there are no studies in neonates on the use of bovine colostrum for the prevention&#xD;
      of NEC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be definite NEC</measure>
    <time_frame>baseline</time_frame>
    <description>Subjects who will be suspected to have NEC (based on clinical features) undergo an abdominal X-ray and stool occult blood assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive statistics will be used for describing baseline variables.Dichotomous outcomes will be compared by Chi square test with continuity correction or Fisher's Exact as applicable.</measure>
    <time_frame>baseline</time_frame>
    <description>Numerical variables will be compared by Student's t-test or Mann Whitney U-test, depending on distribution.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>NEC</condition>
  <arm_group>
    <arm_group_label>Remuverol</arm_group_label>
    <description>The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for &lt; 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>bovine colostrum</intervention_name>
    <description>The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for &lt; 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.</description>
    <arm_group_label>Remuverol</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum&#xD;
        and 1.2 g/dose for &lt; 1000 g stratum, four times a day until discharge or death or day 21 of&#xD;
        life, whichever is earlier.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Babies with birth weight â‰¤ 1500 g&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Babies who have any contraindication for initiating milk feeds; who will fail to&#xD;
             achieve adequate feed volume to be able to administer the study drug.&#xD;
&#xD;
          -  Those with suspected/ proven gastrointestinal malformations.&#xD;
&#xD;
          -  Preexisting sepsis (definite or suspect) or NEC at the time of enrollment.&#xD;
&#xD;
          -  Those with a family history of an inborn error metabolism (that precludes exposure to&#xD;
             proteins/lactose).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mohamed kamal, M.B.B.Ch</last_name>
    <phone>01027507508</phone>
    <email>kemo6555@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohammed gamil, assistant professor</last_name>
    <phone>01024741834</phone>
  </overall_contact_backup>
  <reference>
    <citation>Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs. 2008;68(9):1227-38. Review.</citation>
    <PMID>18547133</PMID>
  </reference>
  <reference>
    <citation>Grave GD, Nelson SA, Walker WA, Moss RL, Dvorak B, Hamilton FA, Higgins R, Raju TN. New therapies and preventive approaches for necrotizing enterocolitis: report of a research planning workshop. Pediatr Res. 2007 Oct;62(4):510-4.</citation>
    <PMID>17667844</PMID>
  </reference>
  <reference>
    <citation>Hoy CM, Wood CM, Hawkey PM, Puntis JW. Duodenal microflora in very-low-birth-weight neonates and relation to necrotizing enterocolitis. J Clin Microbiol. 2000 Dec;38(12):4539-47.</citation>
    <PMID>11101593</PMID>
  </reference>
  <reference>
    <citation>Peter CS, Feuerhahn M, Bohnhorst B, Schlaud M, Ziesing S, von der Hardt H, Poets CF. Necrotising enterocolitis: is there a relationship to specific pathogens? Eur J Pediatr. 1999 Jan;158(1):67-70.</citation>
    <PMID>9950312</PMID>
  </reference>
  <reference>
    <citation>Hoy C, Millar MR, MacKay P, Godwin PG, Langdale V, Levene MI. Quantitative changes in faecal microflora preceding necrotising enterocolitis in premature neonates. Arch Dis Child. 1990 Oct;65(10 Spec No):1057-9.</citation>
    <PMID>2122814</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Kamal Ali Abd El Hameed</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

